Melanoma and Other Skin Cancers

8 protocols meet the specified criteria.
  • 2125-MEL-301

    A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma
  • EA6134

    DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) Trial
  • EAY131

    Molecular Analysis for Therapy Choice (MATCH)
  • INCB54828-207

    A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants with Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
  • INCMGA-0012-201

    A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma
  • S1616

    A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
  • SIMPRO

    SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice.
  • WVU011118

    Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry